drugset / Trial / NCT02293395

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

NCT02293395

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor agent: clopidogrel or ticagrelor), in participants with a recent acute coronary syndrome (ACS: including ST segment elevation myocardial infarction \[STEMI\] and non-ST-segment elevation acute coronary syndrome \[NSTE-ACS\]).

Timeline

Start
2015-04-20
Primary completion
2016-10-14
Completion
2016-10-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg Oral
Subject Rivaroxaban Other / unclassified 2.5 mg Oral
Background Clopidogrel Small molecule 75 mg Oral
Background Ticagrelor Small molecule 90 mg Oral